Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
ESMO Open|January 21, 2023
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trialE de Azambuja, E Agostinetto, M Procter, et al.
ESMO Open|February 13, 2024
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomesM A Franzoi, M Aupomerol, J Havas, et al.
ESMO Open|January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)E Agostinetto, G Pfeiler, D Hlauschek, et al.
ESMO Open|June 12, 2025
Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)A Rossi, A G Leone, M Lambertini, et al.
Techniques in Coloproctology|July 16, 2010
A nationwide audit of the use of radiotherapy for rectal cancer in ItalyG Gagliardi, S Pucciarelli, C R Asteria, et al.
ESMO Open|October 25, 2023
Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysisL Arecco, E Blondeaux, M Bruzzone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2019
Gynecologic cancers in pregnancy: guidelines based on a third international consensus meetingF Amant, P Berveiller, I A Boere, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2019
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysisA R Ferreira, A Di Meglio, B Pistilli, et al.
ESMO Open|August 9, 2024
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trialF Poggio, E Blondeaux, M Tagliamento, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Pageof 7